Plain-English translation of NCT07238816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested a new medication called Inno8 designed to treat hemophilia A. Researchers studied how the timing of meals before and after taking the medication affected how well the body absorbed it. The goal was to understand the best way for patients to take this treatment in everyday life.
When you take any medication by mouth, food in your stomach can affect how well your body absorbs it. This trial was designed to figure out the best eating schedule around taking this medication so patients can get the most benefit from their treatment.
Participants were assigned to one of four groups and received a single dose of the medication after fasting overnight. The length of the fast before and after taking the medication depended on which group they were in. The entire study lasted up to 9.5 weeks, during which researchers monitored how the body processed the medication through blood tests and physical exams.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Sponsor
Novo Nordisk A/S
Enrollment target
~80 participants
Started
November 2025
Primary completion
May 2026
Age range
18 Years – 45 Years
Sex
Male only
Last updated on clinicaltrials.gov in June 2026.